BR0307410A - Uso de inibidores de pde5 no tratamento da cicatrização e fibrose - Google Patents
Uso de inibidores de pde5 no tratamento da cicatrização e fibroseInfo
- Publication number
- BR0307410A BR0307410A BR0307410-2A BR0307410A BR0307410A BR 0307410 A BR0307410 A BR 0307410A BR 0307410 A BR0307410 A BR 0307410A BR 0307410 A BR0307410 A BR 0307410A
- Authority
- BR
- Brazil
- Prior art keywords
- fibrosis
- treatment
- healing
- inhibitors
- pde5 inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"USO DE INIBIDORES DE PDE5 NO TRATAMENTO DA CICATRIZAçãO E FIBROSE". A invenção refere-se ao uso de inibidores de 3',5'-monofosfato de guanosina do tipo cinco (cGMP PDE 5) cíclico (de agora em diante denominados por inibidores de PDE 5), incluindo especificamente o composto sildenafil, para o tratamento da ou para a prevenção da cicatrização ou da fibrose em tecidos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0202254.9A GB0202254D0 (en) | 2002-01-31 | 2002-01-31 | Prevention of scarring |
PCT/IB2003/000134 WO2003063875A1 (en) | 2002-01-31 | 2003-01-21 | Use of pde5 inhibitors in the treatment of scarring and fibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0307410A true BR0307410A (pt) | 2004-12-28 |
Family
ID=9930135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0307410-2A BR0307410A (pt) | 2002-01-31 | 2003-01-21 | Uso de inibidores de pde5 no tratamento da cicatrização e fibrose |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1469857A1 (pt) |
JP (1) | JP2005523263A (pt) |
BR (1) | BR0307410A (pt) |
CA (1) | CA2474852A1 (pt) |
GB (1) | GB0202254D0 (pt) |
MX (1) | MXPA04007430A (pt) |
TW (1) | TW200302105A (pt) |
WO (1) | WO2003063875A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006528229A (ja) * | 2003-05-22 | 2006-12-14 | アルタナ ファルマ アクチエンゲゼルシャフト | Pde4阻害剤及びpde5阻害剤を含有する組成物 |
CN101106997A (zh) | 2004-08-17 | 2008-01-16 | 约翰·霍普金斯大学 | Pde5抑制剂组合物及治疗心脏病征候的方法 |
ATE438403T1 (de) * | 2004-08-19 | 2009-08-15 | Switch Biotech Llc | Verwendung eines pde5-hemmers zur behandlung und vorbeugung von hypopigmentierungsstörungen |
WO2006018088A1 (en) * | 2004-08-19 | 2006-02-23 | Switch Biotech Ag | Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders |
WO2006074443A2 (en) | 2005-01-07 | 2006-07-13 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for immunotherapy |
DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
WO2006111198A1 (en) * | 2005-04-18 | 2006-10-26 | Associazione Foresta Per La Ricerca Nella Riproduzione Umana | Use of pde-5 inhibitors for endothelial repair of tissues impaired by trauma or disease |
CA2611638C (en) | 2005-06-10 | 2010-08-24 | Dong A Pharm. Co. Ltd. | Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative |
AR079451A1 (es) | 2009-12-18 | 2012-01-25 | Nycomed Gmbh | Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina |
KR101377178B1 (ko) * | 2010-04-05 | 2014-03-26 | 에스케이케미칼주식회사 | Pde5 억제제를 함유하는 피부 주름 개선용 조성물 |
ME02207B (me) * | 2010-05-26 | 2016-02-20 | Adverio Pharma Gmbh | UPOTREBA sGC STIMULATORA, sGC AKTIVATORA, POJEDINAČNO I U KOMBINACIJI SA PDE5 INHIBITORIMA ZA TRETMAN SISTEMSKE SKLEROZE (SSc) |
CN103826638B (zh) * | 2011-09-09 | 2015-11-25 | Sk化学公司 | 含有pde5 抑制剂的减少皮肤皱纹的组合物 |
AT512084A1 (de) | 2011-10-20 | 2013-05-15 | Univ Wien Tech | Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren |
ES2700989T3 (es) | 2012-12-21 | 2019-02-20 | Mayo Found Medical Education & Res | Métodos y materiales para tratar estenosis de la válvula aórtica calcificada |
EP2992885A3 (en) * | 2014-09-02 | 2016-05-18 | Jansfat Biotechnology Co., Ltd. | Method for inhibiting a liver disease |
EP4166129A1 (en) | 2017-03-14 | 2023-04-19 | Atir Holding S.A. | Use of heterocyclic compounds in the treatment of aged skin |
WO2018167689A1 (en) | 2017-03-14 | 2018-09-20 | Atir Holding S.A. | Topical formulation for the treatment of pigmented skin |
MX2017016930A (es) * | 2017-12-19 | 2019-06-20 | Malesil Research & Tech Llc | Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico. |
CN112773898A (zh) * | 2019-11-11 | 2021-05-11 | 广州华真医药科技有限公司 | 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US5965501A (en) * | 1997-03-28 | 1999-10-12 | Lever Brothers Company, Division Of Conopco, Inc. | Personal washing bar compositions comprising emollient rich phase/stripe |
AU5067098A (en) * | 1997-11-26 | 1999-06-15 | Mochida Pharmaceutical Co., Ltd. | Pyridocarbazole derivatives with cgmp-pde inhibitory activity |
ZA9810766B (en) * | 1997-11-28 | 1999-05-25 | Mochida Pharm Co Ltd | Novel compounds having cgmp-pde inhibitory activity |
GB9909135D0 (en) * | 1999-04-22 | 1999-06-16 | Univ Wales Medicine | Cystic fibrosis medicaments |
CA2323008C (en) * | 1999-10-11 | 2005-07-12 | Pfizer Inc. | Pharmaceutically active compounds |
GB9930570D0 (en) * | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
-
2002
- 2002-01-31 GB GBGB0202254.9A patent/GB0202254D0/en not_active Ceased
-
2003
- 2003-01-21 EP EP20030734608 patent/EP1469857A1/en not_active Withdrawn
- 2003-01-21 JP JP2003563565A patent/JP2005523263A/ja active Pending
- 2003-01-21 MX MXPA04007430A patent/MXPA04007430A/es unknown
- 2003-01-21 BR BR0307410-2A patent/BR0307410A/pt not_active IP Right Cessation
- 2003-01-21 WO PCT/IB2003/000134 patent/WO2003063875A1/en active Application Filing
- 2003-01-21 CA CA002474852A patent/CA2474852A1/en not_active Abandoned
- 2003-01-24 TW TW092101618A patent/TW200302105A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA04007430A (es) | 2005-06-20 |
JP2005523263A (ja) | 2005-08-04 |
GB0202254D0 (en) | 2002-03-20 |
EP1469857A1 (en) | 2004-10-27 |
CA2474852A1 (en) | 2003-08-07 |
TW200302105A (en) | 2003-08-01 |
WO2003063875A1 (en) | 2003-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0307410A (pt) | Uso de inibidores de pde5 no tratamento da cicatrização e fibrose | |
CY1105390T1 (el) | Θepαπευτικη αγωγη της πνευμονικης υπερτασης | |
MXPA05013637A (es) | Inhibidores gsk-3 y usos de los mismos. | |
DK1636236T3 (da) | Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer | |
NO20075099L (no) | Alkynyl-pyrrolopyrmidiner og relaterte analoger som HSP90-inhibitorer | |
EE200300475A (et) | Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis | |
TNSN03144A1 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
IL184898A0 (en) | Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same | |
NO20064584L (no) | Tetrahydropyridoindolderivater | |
EP1129706A3 (en) | Use of cGMP PDE5 inhibitors for the treatment of neuropathy | |
NO20051647L (no) | Pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer | |
MY144616A (en) | Substituted dihydroquinazolines | |
AP2003002929A0 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
BRPI0406796A (pt) | Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina | |
BRPI0509667A (pt) | azaquinazolinas substituìdas com eficácia antiviral | |
ZA200205694B (en) | Treatment of diabetic ulcers. | |
NO20062229L (no) | Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er) | |
MXPA04005809A (es) | Inhibidores de proteinas quinasas. | |
BRPI0408500A (pt) | tratamento do diabetes do tipo 1 com inibidores de pde5 | |
BR0111785A (pt) | Composições e métodos para tratamento de candidìase | |
BRPI0411168B1 (pt) | Composição para o tratamento dos cabelos, usos da composição e método de tratamento dos cabelos. | |
BR0115413A (pt) | Tratamento de ejaculação precoce | |
WO2002076930A3 (en) | Substituted diarylureas as stimulators for fas-mediated apoptosis | |
AU2003298244A8 (en) | Method for inhibiting the replication of herpes viruses | |
EP1465616A4 (en) | TREATMENT OF SIDE EFFECTS OF STATINE USING URIDINE DERIVATIVES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 8A E 9A ANUIDADE(S). |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 8A E 9A ANUIDADES. |